194 related articles for article (PubMed ID: 25907407)
1. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects.
Nguyen L; Holland J; Mamelok R; Laberge MK; Grenier J; Swearingen D; Armas D; Lacy S
J Clin Pharmacol; 2015 Nov; 55(11):1293-302. PubMed ID: 25907407
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults.
Nguyen L; Benrimoh N; Xie Y; Offman E; Lacy S
Anticancer Drugs; 2016 Aug; 27(7):669-78. PubMed ID: 27139820
[TBL] [Abstract][Full Text] [Related]
3. Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers.
Zhou J; Quinlan M; Glenn K; Boss H; Picard F; Castro H; Sellami D
Br J Clin Pharmacol; 2016 Oct; 82(4):1022-9. PubMed ID: 27277189
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
[TBL] [Abstract][Full Text] [Related]
5. Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole.
Pohl O; Osterloh I; Lecomte V; Gotteland JP
Int J Clin Pharmacol Ther; 2013 Jan; 51(1):26-33. PubMed ID: 23110788
[TBL] [Abstract][Full Text] [Related]
6. Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility.
Ware JA; Dalziel G; Jin JY; Pellett JD; Smelick GS; West DA; Salphati L; Ding X; Sutton R; Fridyland J; Dresser MJ; Morrisson G; Holden SN
Mol Pharm; 2013 Nov; 10(11):4074-81. PubMed ID: 24099279
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
[TBL] [Abstract][Full Text] [Related]
8. Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib.
Nguyen L; Holland J; Ramies D; Mamelok R; Benrimoh N; Ciric S; Marbury T; Preston RA; Heuman DM; Gavis E; Lacy S
J Clin Pharmacol; 2016 Sep; 56(9):1130-40. PubMed ID: 26865195
[TBL] [Abstract][Full Text] [Related]
9. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.
Lau YY; Gu W; Lin T; Viraswami-Appanna K; Cai C; Scott JW; Shi M
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1119-1128. PubMed ID: 28424965
[TBL] [Abstract][Full Text] [Related]
10. When Bioequivalence in Healthy Volunteers May not Translate to Bioequivalence in Patients: Differential Effects of Increased Gastric pH on the Pharmacokinetics of Levothyroxine Capsules and Tablets.
Seng Yue C; Benvenga S; Scarsi C; Loprete L; Ducharme MP
J Pharm Pharm Sci; 2015; 18(5):844-55. PubMed ID: 26670370
[TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib.
Lacy SA; Miles DR; Nguyen LT
Clin Pharmacokinet; 2017 May; 56(5):477-491. PubMed ID: 27734291
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects.
Xu H; O'Gorman M; Boutros T; Brega N; Kantaridis C; Tan W; Bello A
J Clin Pharmacol; 2015 Jan; 55(1):104-13. PubMed ID: 24990113
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis.
Miles D; Jumbe NL; Lacy S; Nguyen L
Clin Pharmacokinet; 2016 Jan; 55(1):93-105. PubMed ID: 26149244
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma.
Rassy E; Cerbone L; Auclin E; Benchimoll-Zouari A; Flippot R; Alves Costa Silva C; Colomba E; Geraud A; Guida A; Mir O; Combarel D; Paci A; Escudier B; Albiges L
Oncologist; 2021 May; 26(5):389-396. PubMed ID: 33554383
[TBL] [Abstract][Full Text] [Related]
15. The Relative Bioavailability and Effects of Food and Acid-Reducing Agents on Filgotinib Tablets in Healthy Subjects.
Anderson K; Zheng H; Kotecha M; Cuvin J; Scott B; Sharma S; Qin AR; Namour F; Xin Y
Clin Pharmacol Drug Dev; 2019 Jul; 8(5):585-594. PubMed ID: 30768860
[TBL] [Abstract][Full Text] [Related]
16. Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH.
Schmitt-Hoffmann A; Desai A; Kowalski D; Pearlman H; Yamazaki T; Townsend R
Int J Clin Pharmacol Ther; 2016 Aug; 54(8):572-80. PubMed ID: 27345284
[TBL] [Abstract][Full Text] [Related]
17. Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects.
Morcos PN; Guerini E; Parrott N; Dall G; Blotner S; Bogman K; Sturm C; Balas B; Martin-Facklam M; Phipps A
Clin Pharmacol Drug Dev; 2017 Jul; 6(4):388-397. PubMed ID: 27545320
[TBL] [Abstract][Full Text] [Related]
18. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.
Kraft WK; Chang PS; van Iersel ML; Waskin H; Krishna G; Kersemaekers WM
Antimicrob Agents Chemother; 2014 Jul; 58(7):4020-5. PubMed ID: 24798274
[TBL] [Abstract][Full Text] [Related]
19. A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.
Malhi V; Colburn D; Williams SJ; Hop CE; Dresser MJ; Chandra P; Graham RA
Cancer Chemother Pharmacol; 2016 Jul; 78(1):41-9. PubMed ID: 27154174
[TBL] [Abstract][Full Text] [Related]
20. Effect of esomeprazole with/without acetylsalicylic acid, omeprazole and lansoprazole on pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Andersson T; Nagy P; Niazi M; Nylander S; Galbraith H; Ranjan S; Wallentin L
Am J Cardiovasc Drugs; 2014 Jun; 14(3):217-27. PubMed ID: 24677117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]